HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gunn, R. N. Articles by Cunningham, V. J. Search for Related Content PubMed PubMed Citation Articles by Gunn, R. N. Articles by Cunningham, V. J.

A General Method to Correct PET Data for Tissue Metabolites Using a Dual-Scan Approach

MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom

Correspondence: For correspondence or reprints contact: Roger N. Gunn, PhD, MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, DuCane Rd., London W12 0NN, UK.

ABSTRACT

This article presents and analyses a general method of correcting for the presence of radiolabeled metabolites from a parent radiotracer in tissue during PET scanning. The method is based on a dual-scan approach, i.e., parent scan together with an independent supplementary scan in which the radiolabeled metabolite of interest itself is administered. The method corrects for the presence of systemically derived radiolabeled metabolite delivered to the tissues of interest through the blood. Methods: Data from the supplementary scan are analyzed to obtain the tissue impulse response function for the metabolite. The time course of the radiolabeled metabolite in plasma in the parent scan is convolved with its tissue impulse response function to derive a correction term. This is not a simple subtraction technique but 1 that takes account of the different time-activity curves of the radiolabeled metabolite in the 2 scans. Results: The method, its implications, and its limitations are discussed with respect to [¹¹C]thymidine and its principal metabolite ¹¹CO₂. Conclusion: The general method, based on a dual-scan approach, can be used to correct for radiolabeled metabolites in tissues of interest during PET scanning. The correction accounts for radiolabeled metabolites that are derived systemically and delivered to the tissues of interest through the blood.

Key Words: PET • metabolites • kinetic analysis

This article has been cited by other articles:

				A. F. Shields, J. M. Lawhorn-Crews, D. A. Briston, S. Zalzala, S. Gadgeel, K. A. Douglas, T. J. Mangner, L. K. Heilbrun, and O. Muzik Analysis and Reproducibility of 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., July 15, 2008; 14(14): 4463 - 4468. [Abstract] [Full Text] [PDF]

				J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF]

				P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, and J. Zweit Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst, May 3, 2006; 98(9): 580 - 598. [Abstract] [Full Text] [PDF]

				P. Wells, R. N. Gunn, C. Steel, A. S. Ranicar, F. Brady, S. Osman, T. Jones, and P. Price 2-[11C]Thymidine Positron Emission Tomography Reproducibility in Humans Clin. Cancer Res., June 15, 2005; 11(12): 4341 - 4347. [Abstract] [Full Text] [PDF]

				A. Saleem, G. D. Brown, F. Brady, E. O. Aboagye, S. Osman, S. K. Luthra, A. S. O. Ranicar, C. S. Brock, M. F. G. Stevens, E. Newlands, et al. Metabolic Activation of Temozolomide Measured in Vivo Using Positron Emission Tomography Cancer Res., May 15, 2003; 63(10): 2409 - 2415. [Abstract] [Full Text] [PDF]

				P. Wells, E. Aboagye, R. N. Gunn, S. Osman, A. V. Boddy, G. A. Taylor, I. Rafi, A. N. Hughes, A. H. Calvert, P. M. Price, et al. 2-[11C]Thymidine Positron Emission Tomography as an Indicator of Thymidylate Synthase Inhibition in Patients Treated With AG337 J Natl Cancer Inst, May 7, 2003; 95(9): 675 - 682. [Abstract] [Full Text] [PDF]

				P. Wells, R. N. Gunn, M. Alison, C. Steel, M. Golding, A. S. Ranicar, F. Brady, S. Osman, T. Jones, and P. Price Assessment of Proliferation in Vivo Using 2-[11C]Thymidine Positron Emission Tomography in Advanced Intra-abdominal Malignancies Cancer Res., October 15, 2002; 62(20): 5698 - 5702. [Abstract] [Full Text] [PDF]